China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first phase of its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang province. The first phase of the project, covering an area of 58,000 square meters and with an investment of more than RMB 900 million (USD 129 million), includes a set of advanced production facilities built to meet global and China GMP standards. The facility was designed with an annual production capacity of 700 million doses of mRNA vaccines.
Development and Strategic Partnerships
Everest is actively advancing the development of mRNA COVID-19 vaccines and formed a strategic cooperation agreement with Providence Therapeutics Holdings Inc. in September 2021. The firm now has independent capabilities to develop and produce mRNA vaccines and innovative drugs, according to the press release. The successful trial production runs at the Jiashan facility mark a significant step forward in Everest’s commitment to expanding its mRNA vaccine production capabilities.
Future Prospects and Strategic Implications
The initiation of the first phase of the global manufacturing site in Jiashan positions Everest Medicines to further enhance its presence in the mRNA vaccine market. By leveraging advanced production facilities and strategic partnerships, Everest aims to address significant unmet medical needs and contribute to global efforts in combating COVID-19 and other infectious diseases.-Fineline Info & Tech
